Phenylephrine

Category
stimulant
Routes
Oral (PO)
Half-Life (t½)
PO: 6h
Formula
C9H13NO2
Molecular Weight
167.21 g/mol
PubChem CID
6041
Aliases
Sudafed PE, neo-synephrine

Pharmacological Mechanism

α1-adrenergic agonist with minimal β activity. OTC oral decongestant since the 2006 Combat Methamphetamine Epidemic Act moved pseudoephedrine behind-the-counter; the active in Sudafed PE, Vicks Sinex, and most non-drowsy cold formulations. FDA Sept 2023 NDAC voted that oral phenylephrine at standard 10 mg PO doses is ineffective for nasal congestion (heavy first-pass via SULT1A3 reduces oral F to ~38%, much pre-systemic). Intranasal and IV routes work; IV used in anesthesia for hypotension.

Half-Life & Elimination Curve (PO: 6h)

100%50%25%12.5%0%0h0×t½6h1×t½12h2×t½18h3×t½24h4×t½30h5×t½0×t½ (0h): 100% remaining1×t½ (6h): 50% remaining2×t½ (12h): 25% remaining3×t½ (18h): 12.5% remaining4×t½ (24h): 6.3% remaining5×t½ (30h): 3.1% remaining
Elimination (PO)
  • 0×t½0h100%
  • 1×t½6h50%
  • 2×t½12h25%
  • 3×t½18h12.5%
  • 4×t½24h6.3%
  • 5×t½30h3.1%
Elimination t½6h (PO)
Rate Constant (ke)0.116 h⁻¹
97% Washout (5×t½)30h

Dosing Guidelines

Pathways It Modulates

Target Organ Systems

Notes

Behind-the-counter in US. Avoid with hypertension.

Chemical Structure & Identifiers

References